SPRYD5 Activators
SPRYD5 can regulate its activity through various molecular mechanisms. Forskolin directly targets adenylyl cyclase to ramp up cyclic AMP (cAMP) levels within cells. The surge in cAMP leads to the activation of Protein Kinase A (PKA), which is known to phosphorylate target proteins, including SPRYD5, thus promoting its activation. Similarly, IBMX works to sustain elevated cAMP levels by inhibiting phosphodiesterases, which otherwise break down cAMP, thus facilitating a prolonged PKA signaling and subsequent activation of SPRYD5. Epinephrine, a hormone and a neurotransmitter, engages with adrenergic receptors and triggers a signaling cascade that culminates in increased cAMP production, thereby activating PKA, which then can act on SPRYD5. Additionally, Prostaglandin E1 (PGE1) interacts with its own set of G protein-coupled receptors, effectuating a rise in cAMP and PKA activation, which in turn can lead to the phosphorylation and activation of SPRYD5.
Rolipram, a selective phosphodiesterase-4 inhibitor, and Sildenafil, a phosphodiesterase-5 inhibitor, both work to prevent the breakdown of cAMP and cGMP respectively, leading to enhanced PKA activity and potential activation of SPRYD5. Dibutyryl-cAMP, a cAMP analog, bypasses upstream signaling and directly increases cAMP levels, leading to PKA activation and SPRYD5 activation. Anisomycin, although primarily a protein synthesis inhibitor, can activate stress-activated protein kinases, which may phosphorylate SPRYD5. The modulation of SPRYD5 activity is also plausible with the use of Piceatannol and SP600125, which impact secondary signaling pathways due to their inhibition of Syk kinase and c-Jun N-terminal kinase (JNK) respectively. Lastly, Y-27632, a ROCK inhibitor, can alter cytoskeletal dynamics, which may influence signaling pathways that activate SPRYD5. These chemical activators, through distinct pathways, all converge on the regulation of SPRYD5 activity via phosphorylation, a key post-translational modification that controls protein function.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
Isobutylmethylxanthine (IBMX) inhibits phosphodiesterases, preventing the breakdown of cAMP. This results in increased cAMP levels within the cell, which can activate PKA. PKA activation can lead to subsequent phosphorylation and activation of SPRYD5. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $41.00 $104.00 $201.00 $1774.00 $16500.00 | ||
Epinephrine binds to adrenergic receptors, which can lead to an increase in intracellular cAMP levels through G protein-coupled receptor signaling. The resulting activation of PKA can promote SPRYD5 activation via phosphorylation. | ||||||
PGE1 (Prostaglandin E1) | 745-65-3 | sc-201223 sc-201223A | 1 mg 10 mg | $31.00 $145.00 | 16 | |
Prostaglandin E1 (PGE1) binds to its G protein-coupled receptor, leading to increased cAMP production. The cAMP activates PKA, which in turn can phosphorylate and activate SPRYD5. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram is a selective phosphodiesterase-4 inhibitor, which prevents the breakdown of cAMP, leading to increased cAMP levels. This amplifies PKA signaling, which could then lead to the phosphorylation and activation of SPRYD5. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
Anisomycin is a protein synthesis inhibitor that can activate stress-activated protein kinases (SAPKs) which may phosphorylate and activate SPRYD5 as part of the cellular stress response. | ||||||
Piceatannol | 10083-24-6 | sc-200610 sc-200610A sc-200610B | 1 mg 5 mg 25 mg | $51.00 $71.00 $199.00 | 11 | |
Piceatannol can inhibit Syk kinase, which might lead to alterations in downstream signaling pathways that could result in the activation of SPRYD5 through compensatory cellular mechanisms involving crosstalk with other signaling pathways. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which can lead to the modification of signaling pathways and potentially the activation of SPRYD5 through a compensatory response in the cellular signaling network. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a ROCK inhibitor which may lead to changes in cytoskeletal dynamics, potentially influencing signaling pathways that could lead to the activation of SPRYD5, as the protein may interact with components affected by ROCK activity. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Zaprinast is another phosphodiesterase inhibitor with specificity toward PDE5, like Sildenafil, and can also inhibit PDE6. By preventing cGMP breakdown, it indirectly may lead to increased cAMP and PKA activity, possibly leading to SPRYD5 activation. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $47.00 $136.00 $492.00 $4552.00 | 74 | |
Dibutyryl-cAMP is a cell-permeable cAMP analog that directly increases intracellular cAMP levels, thereby activating PKA which can phosphorylate and activate SPRYD5. | ||||||